6:01 PM
Jun 25, 2008
 |  BC Extra  |  Top Story

NICE ends Avastin, Gliadel, Erbitux reviews

The U.K.'s NICE said it is unable to recommend the use of Avastin bevacizumab, Gliadel carmustine implants and Erbitux cetuximab in certain cancer treatments after the drugs' manufacturers provided insufficient evidence to allow for an appraisal. NICE ended the following reviews: Avastin in combination with paclitaxel for first-line metastatic breast cancer; Avastin plus platinum-based chemotherapy in first-line treatment of inoperable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC);...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >